Lyphe Group secures £5m in funding led by Leafy Tunnel
Summary
None The funds are being used for expansion into multiple markets across Europe with Lyphes proprietary dispensing software and vertically integrated supply chain. We are fully aligned with the companys roadmap towards securing a leading market position in Europe and look forward to supporting the management in achieving Lyphe Groups next milestones. Newly appointed CEO, Jonathan Nadler has been influential in establishing the foundations of the UK medical cannabis industry, and since co-founding Lyphe, has dedicated his life to building access and demand. He sits on the board with Mr Fisher alongside the other Executive Team, James Scarth and Chris Ashton, as well as Non-Executive Directors Simon Lawley, Brad Morris, and Sarah Cope.Lyphe has built a digital first patient-access ecosystem that provides clinics, dispensing, import infrastructure and vital educational services to patients, doctors and the industry. Each operating company shares a central goal to pioneer patient access to safe and effective treatments while normalising cannabis into mainstream healthcare.Leafy Tunnel Ltd, an early-stage venture capital firm, acts as the investment adviser to Leafy Tunnel Fund 1, a Guernsey-based fund which invests in European medical cannabis and global medical psychedelics companies at Seed and Series A stages.